GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Wandong Medical Technology Co 600055.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.40

-1.70%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.34bn

FY2016FY2025

Net income

−CN¥227.9m

FY2016FY2025

Free cash flow

−CN¥351.0m

FY2016FY2025

Shareholders' equity

CN¥4.46bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.34bnCN¥1.52bnCN¥1.24bnCN¥1.12bnCN¥1.16bnCN¥1.13bnCN¥982.4mCN¥954.5mCN¥884.0mCN¥813.4m
Gross profitCN¥324.8mCN¥550.7mCN¥517.2mCN¥491.3mCN¥522.2mCN¥555.6mCN¥456.3mCN¥409.8mCN¥360.1mCN¥309.3m
Research and developmentCN¥244.9mCN¥171.7mCN¥157.6mCN¥137.8mCN¥111.5mCN¥86.4mCN¥70.2mCN¥61.9mCN¥61.5mCN¥65.5m
Operating income−CN¥370.8mCN¥163.3mCN¥213.3mCN¥192.5mCN¥208.7mCN¥264.0mCN¥188.9mCN¥177.2mCN¥116.8mCN¥49.3m
Net income−CN¥227.9mCN¥157.4mCN¥188.5mCN¥175.4mCN¥183.2mCN¥220.7mCN¥168.9mCN¥153.3mCN¥109.1mCN¥71.5m
Diluted earnings per share-0.320.220.270.250.350.420.310.280.190.13

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥5.76bnCN¥5.47bnCN¥5.40bnCN¥5.26bnCN¥2.88bnCN¥2.86bnCN¥2.57bnCN¥2.44bnCN¥2.32bnCN¥2.20bn
Cash and short-term investmentsCN¥3.27bnCN¥3.59bnCN¥3.44bnCN¥3.34bnCN¥1.13bnCN¥1.17bnCN¥736.2mCN¥349.8mCN¥538.3mCN¥750.5m
Total liabilitiesCN¥1.18bnCN¥592.5mCN¥575.7mCN¥552.0mCN¥372.9mCN¥480.2mCN¥382.6mCN¥421.9mCN¥420.0mCN¥345.5m
DebtCN¥438.3mCN¥26.5mCN¥17.6mCN¥22.6mCN¥19.0mCN¥82.9mCN¥434,349CN¥4.2mCN¥4.2mCN¥4.2m
Shareholders' equityCN¥4.46bnCN¥4.77bnCN¥4.71bnCN¥4.61bnCN¥2.40bnCN¥2.28bnCN¥2.09bnCN¥1.96bnCN¥1.84bnCN¥1.79bn
Shares outstanding702m706m695m704m524m522m541m543m564m555m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−CN¥252.0mCN¥218.3mCN¥208.2mCN¥185.4mCN¥89.7mCN¥520.0mCN¥94.8mCN¥75.5m−CN¥77.7mCN¥102.7m
Capital spending−CN¥99.0m−CN¥38.6m−CN¥17.1m−CN¥14.0m−CN¥11.9m−CN¥23.1m−CN¥41.4m−CN¥42.6m−CN¥50.9m−CN¥21.4m
Free cash flow−CN¥351.0mCN¥179.6mCN¥191.1mCN¥171.4mCN¥77.9mCN¥496.9mCN¥53.4mCN¥32.9m−CN¥128.6mCN¥81.4m
Dividends paid−CN¥91.4m−CN¥91.4m−CN¥84.4m−CN¥70.3m−CN¥69.7m−CN¥26.8m−CN¥54.0m−CN¥27.0m−CN¥57.9m−CN¥23.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥468.1mCN¥406.6mCN¥158.5mCN¥345.2mCN¥470.1mCN¥373.3mCN¥431.3mCN¥393.0m
Gross profitCN¥117.3mCN¥100.9m−CN¥36.4mCN¥91.8mCN¥155.0mCN¥140.9mCN¥131.7mCN¥142.9m
Operating income−CN¥56.1m−CN¥18.0m−CN¥298.4m−CN¥79.2mCN¥19.2mCN¥38.9mCN¥24.1mCN¥37.3m
Net income−CN¥75.7m−CN¥15.9m−CN¥200.7m−CN¥78.5mCN¥16.2mCN¥35.1mCN¥41.6mCN¥31.0m
Diluted earnings per share-0.11-0.02-0.29-0.110.020.050.060.04
Cash from operations——CN¥148.0m−CN¥66.0m−CN¥126.0m−CN¥208.0mCN¥192.0mCN¥26.0m
Capital spending−CN¥40.0m−CN¥10.0m−CN¥45.0m−CN¥12.0m−CN¥8.0m−CN¥32.0m−CN¥1.0m−CN¥4.0m
Free cash flow——CN¥103.0m−CN¥78.0m−CN¥134.0m−CN¥240.0mCN¥191.0mCN¥22.0m
Total assetsCN¥5.24bnCN¥5.40bnCN¥5.76bnCN¥5.70bnCN¥5.52bnCN¥5.40bnCN¥5.47bnCN¥5.33bn
Cash and short-term investments——CN¥3.27bnCN¥3.12bnCN¥3.14bnCN¥3.35bnCN¥3.59bnCN¥3.37bn
Debt——CN¥424.7mCN¥214.9mCN¥7.9mCN¥68.6mCN¥5.4mCN¥77.3m
Shareholders' equityCN¥4.34bnCN¥4.44bnCN¥4.46bnCN¥4.68bnCN¥4.73bnCN¥4.80bnCN¥4.77bnCN¥4.74bn

Financial ratios

Data as of 4 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin24.2%36.1%41.8%43.8%45.2%49.1%
Operating margin-27.7%10.7%17.2%17.2%18.1%23.3%
Net margin-17.0%10.3%15.2%15.6%15.8%19.5%
Return on equity-5.1%3.3%4.0%3.8%7.6%9.7%
Return on assets-4.0%2.9%3.5%3.3%6.4%7.7%
Free cash flow yield-2.1%3.4%3.1%2.7%1.8%9.8%
Revenue growth-12.1%23.3%10.3%-3.0%2.1%15.2%
Earnings growth-244.8%-16.5%7.5%-4.3%-17.0%30.7%
Current ratio4.01x8.32x8.38x8.67x5.67x4.16x
Debt to equity0.10x0.00x0.00x0.00x0.00x0.03x
Equity ratio77.4%87.2%87.3%87.5%83.3%79.8%
Interest coverage-168.89x74.01x125.66x105.10x106.66x79.28x
R&D as a share of sales18.3%11.3%12.7%12.3%9.6%7.6%
Buybacks as a share of market value0.5%-1.5%1.2%-34.2%-0.5%3.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.1%3.4%5.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin30.6%36.1%39.4%39.8%
Operating margin-7.2%3.8%8.9%10.2%
Net margin-2.5%5.6%9.3%10.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-48.067.763.078.468.123.933.130.782.3100.4
Price to sales8.27.09.612.310.84.75.74.910.28.8

Dividends and splits

Per share, in the currency the company pays

Paid for 13 years. Last went ex-dividend on 16 May 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.130.130.120.100.130.050.100.05
  • 7-for-5 split · 2 Jun 2017
  • 8-for-5 split · 27 Jun 2016
  • 3-for-2 split · 6 Jun 2008
  • 1-to-1 reverse split · 11 Apr 2006
  • 13-for-10 split · 14 Jun 2004
  • 2-for-1 split · 7 Apr 1998

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.